Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors

References

• Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–919.
   PubMed Web of Science ®Google Scholar
• Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis: a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067–1077.
   PubMed Web of Science ®Google Scholar
• Uppala R, Tsoi LC, Harms PW, et al. Autoinflammatory psoriasis: genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307–317.
   PubMed Web of Science ®Google Scholar
• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799.
   PubMed Web of Science ®Google Scholar
• Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529–541.
   PubMed Web of Science ®Google Scholar
• Borges-Costa J, Silva R, Gonçalves L, et al. Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am J Clin Dermatol. 2011;12(4):271–276.
   PubMed Web of Science ®Google Scholar
• Ohata C, Tsuruta N, Yonekura K, et al. Clinical characteristics of Japanese pustular psoriasis: a multicenter observational study. J Dermatol. 2021;49(1):142–150.
   PubMed Web of Science ®Google Scholar
• Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global effisayil 1 phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3):e043666.
   PubMedGoogle Scholar
• Kalb RE. Pustular psoriasis: pathogenesis, clinical manifestations, and diagnosis. Waltham, MA: UptoDate; 2021.
   Google Scholar
• Byrne J, Baker K, Houston A, et al. IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymore. Cell Mol Life Sci. 2021;78(17-18):6215–6227.
   PubMed Web of Science ®Google Scholar
• Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology. 2019;143(3):1021–1026.
   PubMed Web of Science ®Google Scholar
• Milora KA, Fu H, Dubaz O, et al. Unprocessed interleukin-36α regulates psoriasis-like skin inflammation in cooperation with interleukin-1. J Invest Dermatol. 2015;135(12):2992–3000.
   PubMed Web of Science ®Google Scholar
• Zheng J, Chen W, Gao Y, et al. Clinical analysis of generalized pustular psoriasis in Chinese patients: a retrospective study of 110 patients. J Dermatol. 2021;48(9):1336–1342.
   PubMed Web of Science ®Google Scholar
• Jin H, Cho HH, Kim WJ, et al. Clinical features and course of generalized pustular psoriasis in Korea. J Dermatol. 2015;42(7):674–678.
   PubMed Web of Science ®Google Scholar
• Takeichi T, Akiyama M. Generalized pustular psoriasis: clinical management and update on autoinflammatory aspects. Am J Clin Dermatol. 2020;21(2):227–236.
   PubMed Web of Science ®Google Scholar
• Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235–1270.
   PubMed Web of Science ®Google Scholar
• Zhu T, Jin H, Shu D, et al. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis. Eur J Dermatol. 2018;28(2):217–224.
   PubMed Web of Science ®Google Scholar
• Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266–1274.
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186(4):2613–2622.
   PubMed Web of Science ®Google Scholar
• Kołt-Kamińska M, Żychowska M, Reich A. Infliximab in combination with low-dose acitretin in generalized pustular psoriasis: a report of two cases and review of the literature. Biologics. 2021;15:317–327.
   PubMed Web of Science ®Google Scholar
• Capon F. IL36RN mutations in generalized pustular psoriasis: just the tip of the iceberg? J Invest Dermatol. 2013;133(11):2503–2504.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133(11):2514–2521.
   PubMed Web of Science ®Google Scholar
• Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016;152(7):825–828.
   PubMed Web of Science ®Google Scholar
• Strober BE, Bissonnette R, Fiorentino D, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (psoriasis longitudinal assessment and registry [PSOLAR]). J Am Acad Dermatol. 2016;74(5):851.e4–861.e4.
   Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539.
   PubMed Web of Science ®Google Scholar
• Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. 2015;173(1):239–241.
   PubMed Web of Science ®Google Scholar
• Skendros P, Papagoras C, Lefaki I, et al. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition. Br J Dermatol. 2017;176(1):212–215.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362.
   PubMed Web of Science ®Google Scholar
• Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work. J Dermatol. 2018;45(11):1353–1356.
   PubMed Web of Science ®Google Scholar
• Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, et al. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol. 2018;45(7):850–854.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Catapano M, Meglio PD, et al. An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target. Sci Transl Med. 2017;9(411):eaan2514.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–1613.
   PubMed Web of Science ®Google Scholar
• Bassoy EY, Towne JE, Gabay C. Regulation and function of interleukin-36 cytokines. Immunol Rev. 2018;281(1):169–178.
   PubMed Web of Science ®Google Scholar
• Gresnigt MS, van de Veerdonk FL. Biology of IL-36 cytokines and their role in disease. Semin Immunol. 2013;25(6):458–465.
   PubMed Web of Science ®Google Scholar
• Iznardo H, Puig L. Exploring the role of IL-36 cytokines as a new target in psoriatic disease. Int J Mol Sci. 2021;22(9):4344.
   PubMed Web of Science ®Google Scholar
• Boutet M-A, Nerviani A, Pitzalis C. IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation: a comprehensive review of their therapeutic potential. IJMS. 2019;20(6):1257.
   Google Scholar
• Foster AM, Baliwag J, Chen CS, et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol. 2014;192(12):6053–6061.
   PubMed Web of Science ®Google Scholar
• Honma M, Nozaki H. Molecular pathogenesis of psoriasis and biomarkers reflecting disease activity. J Clin Med. 2021;10(15):3199.
   PubMed Web of Science ®Google Scholar
• Arakawa A, Vollmer S, Besgen P, et al. Unopposed IL-36 activity promotes clonal CD4+ T-cell responses with IL-17A production in generalized pustular psoriasis. J Invest Dermatol. 2018;138(6):1338–1347.
   PubMed Web of Science ®Google Scholar
• Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci. 2014;74(3):187–192.
   PubMed Web of Science ®Google Scholar
• Zhou J, Luo Q, Cheng Y, et al. An update on genetic basis of generalized pustular psoriasis. Int J Mol Med. 2021;47(6):118.
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109–120.
   PubMed Web of Science ®Google Scholar
• Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432–437.
   PubMed Web of Science ®Google Scholar
• Su Z, Paulsboe S, Wetter J, et al. IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis. Exp Dermatol. 2019;28(2):113–120.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981–983.
   PubMed Web of Science ®Google Scholar
• Baum P, Visvanathan S, Garcet S, et al. Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022;149(4):1402–1412.
   PubMed Web of Science ®Google Scholar
• A study to test BI 655130 in patients with a flare-up of a skin disease called generalized pustular psoriasis. Available from: https://ClinicalTrials.gov/show/NCT03782792
   Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–2440.
   PubMed Web of Science ®Google Scholar
• A 5-year study to test BI 655130 in patients with generalized pustular psoriasis who took part in previous studies with BI 655130. Available from: https://ClinicalTrials.gov/show/NCT03886246
   Google Scholar
• A study to test whether BI 655130 (Spesolimab) prevents flare-ups in patients with generalized pustular psoriasis. Available from: https://ClinicalTrials.gov/show/NCT04399837
   Google Scholar
• Mrowietz U, Burden AD, Pinter A, et al. Spesolimab, an anti-Interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatol Ther (Heidelb). 2021;11(2):571–585.
   PubMed Web of Science ®Google Scholar
• A study to test how effective and safe different doses of BI 655130 are in patients with a moderate to severe form of the skin disease palmoplantar pustulosis. Available from: https://ClinicalTrials.gov/show/NCT04015518
   Google Scholar
• A study to evaluate the efficacy and safety of ANB019 in subjects with palmoplantar pustulosis. Available from: https://ClinicalTrials.gov/show/NCT03633396
   Google Scholar
• A study to evaluate the efficacy and safety of ANB019 in subjects with generalized pustular psoriasis. Available from: https://ClinicalTrials.gov/show/NCT03619902
   Google Scholar
• GlobeNewswire. AnaptysBio presents updated data from imsidolimab phase 2 GALLOP trial in generalized pustular psoriasis 2021. Available from: https://www.globenewswire.com/news-release/2021/10/02/2307446/0/en/AnaptysBio-Presents-Updated-Data-From-Imsidolimab-Phase-2-GALLOP-Trial-in-Generalized-Pustular-Psoriasis.html
   Google Scholar
• AnaptysBio Inc. Imsidolimab 2021. Available from: https://www.anaptysbio.com/pipeline/imsidolimab/
   Google Scholar
• AnaptysBio Inc. AnaptysBio reports Imsidolimab POPLAR phase 2 clinical trial in moderate-to-severe palmoplantar pustulosis (PPP) did not meet primary endpoint 2021. Available from: https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-reports-imsidolimab-poplar-phase-2-clinical-trial/
   Google Scholar
• Zhou LL, Georgakopoulos JR, Ighani A, et al. Systemic monotherapy treatments for generalized pustular psoriasis: a systematic review. J Cutan Med Surg. 2018;22(6):591–601.
   PubMed Web of Science ®Google Scholar